Yes, methotrexate can cause photosensitivity, and it does so through at least two distinct routes: a direct drug-to-light interaction in the skin, and an indirect amplification of ultraviolet damage by blocking the body's folate-dependent DNA repair machinery. The reaction is not universal and is far less common than the photosensitivity tied to tetracyclines or thiazides, but it is documented in the dermatology literature and listed among the drug's cutaneous adverse effects. The clinically important point is that it can appear at any dose, including the low weekly doses used for rheumatoid arthritis and psoriasis.
The Two Mechanisms Behind Methotrexate Photosensitivity
Methotrexate is a folate antagonist. It binds dihydrofolate reductase and stalls the conversion of dihydrofolate to tetrahydrofolate, which throttles thymidylate synthesis and, downstream, DNA replication. That is the therapeutic mechanism in rapidly dividing cells, and it is also the first clue to why skin reacts to light.
The second clue is chemical. Methotrexate is a pteridine derivative with a conjugated aromatic ring system. Molecules with that structure can absorb ultraviolet and visible photons, reach an excited state, and transfer that energy to oxygen or to cellular macromolecules. The result is reactive oxygen species, lipid peroxidation, and localized inflammation. This is the same photochemical logic that explains photosensitivity from other aromatic drugs, though methotrexate's absorption profile and photostability make it a weaker photosensitizer than classic offenders.
The third pathway is indirect and probably the most relevant at low doses. Folate is required for nucleotide excision repair, the pathway that removes cyclobutane pyrimidine dimers after UV exposure. By depleting intracellular folate pools, methotrexate can slow that repair. The skin then accumulates UV damage it would otherwise have fixed. In plain terms: the drug does not just make skin more sensitive to sunlight; it can make skin worse at repairing the damage sunlight causes.
Which mechanism dominates in a given patient is unresolved. Most case reports describe photoexacerbation of existing psoriasis or eczematous eruptions rather than a clean phototoxic burn, which suggests the repair-deficit route matters more than direct photochemistry at standard doses.
How Often It Actually Happens
Precise incidence is not established for methotrexate specifically. Photosensitivity appears in dermatology reviews and drug-reaction registries as an uncommon cutaneous adverse effect, not a common one. That contrasts with drugs where photosensitivity is a headline reaction, such as doxycycline, where phototoxic reactions are frequent enough to drive counseling at every prescription.
The dosing context matters. Weekly low-dose methotrexate, typically in the range used for inflammatory arthritis and psoriasis, is the setting where most photosensitivity reports arise, partly because those patients are already photosensitive from their underlying disease. Psoriasis in particular confounds the picture: UV light is a standard treatment for psoriasis, and disease flares after sun exposure can reflect the disease rather than the drug.
Age and cumulative exposure add background risk. Photodamage accumulates over decades, so a patient starting methotrexate at 60 has a different skin substrate than one starting at 25. Folate status, kidney function, and concurrent drugs that also deplete folate or sensitize skin all shift the threshold. There is no validated dose below which photosensitivity can be excluded.
Timeline: When Reactions Appear
| Timeframe | What is typically observed | Clinical implication |
|---|---|---|
| Days to weeks after starting | First reports of exaggerated sunburn or eczematous eruption in sun-exposed areas | Highest suspicion window for a new drug reaction |
| Within hours of intense exposure | Acute phototoxic pattern: erythema, burning, edema in exposed skin | Suggests direct photochemical mechanism |
| Weeks to months | Photoexacerbation of psoriasis or eczema, sometimes mistaken for disease flare | Hardest to attribute; requires exposure history |
| After dose escalation | New or worsening photosensitivity | Consider dose-response relationship |
| After drug withdrawal | Gradual resolution over weeks | Supports drug causality |
| With continued use and sun protection | Symptoms often controlled without stopping therapy | Practical management option |
The table reflects the general pattern in case reports, not a controlled natural history. Individual timing varies widely, and some patients never react.
Edge Cases That Change the Picture
Several situations raise the index of suspicion or change management.
Patients with psoriasis on methotrexate occupy the most confusing category. Sun exposure is therapeutic for psoriasis, so a flare after sun can be disease, drug, or both. The counterintuitive detail worth flagging: phototherapy and methotrexate are sometimes combined deliberately, and the combination is used clinically, which argues against an absolute prohibition on UV exposure during treatment.
Patients with folate deficiency, whether from diet, alcohol, or malabsorption, may be more vulnerable because the repair-deficiency mechanism is already primed. Patients on concurrent photosensitizing drugs, including some antibiotics, diuretics, and nonsteroidal anti-inflammatory drugs, face additive risk that is easy to miss because each drug alone seems low-risk.
Renal impairment matters because methotrexate clearance falls, raising intracellular exposure and prolonging the folate blockade. Older adults with thinner skin and accumulated photodamage react at lower exposures. Patients with connective tissue disease, particularly lupus, have independent photosensitivity that can be misattributed to methotrexate.
Common Misconceptions
The most common misconception is that methotrexate is a classic photosensitizer on par with doxycycline or hydrochlorothiazide. It is not. The reaction is reported, plausible, and mechanistically coherent, but it is uncommon, and most patients on methotrexate never develop it.
A second misconception is that photosensitivity means an allergy. True photoallergy is immune-mediated and rare; most drug photosensitivity is phototoxic, meaning it does not require prior sensitization and can occur on first exposure. Methotrexate reports are mostly consistent with the phototoxic and repair-deficit patterns.
A third is that sun avoidance must be absolute. Dermatology practice generally favors broad-spectrum sunscreen, protective clothing, and avoidance of peak-intensity sun rather than complete withdrawal from outdoor life. The professional caveat: there is no validated threshold exposure or serum level that predicts who will react, so counseling is precautionary rather than personalized.
A fourth misconception conflates methotrexate with its cousin class. Aminopterin and other antifolates have their own profiles, and experience with one does not automatically transfer. Similarly, topical methotrexate is not systemically absorbed to a meaningful degree, so its photosensitivity risk is not equivalent to oral or injectable therapy.
Practical Actions and Red-Flag Warnings
Concrete steps, in order of importance:
Use broad-spectrum sunscreen with SPF 30 or higher on all exposed skin, reapplied every two hours during sustained outdoor exposure. This is the single highest-yield intervention. Wear tightly woven clothing, a wide-brimmed hat, and sunglasses for prolonged outdoor time, especially between mid-morning and mid-afternoon when UV index peaks. Review the full medication list with a pharmacist for other photosensitizing drugs, since additive risk is the most modifiable factor. Photograph any new rash in sun-exposed distribution, with dates, to distinguish drug reaction from disease flare. Raise any blistering, severe burning, or rash spreading beyond sun-exposed skin with the prescribing clinician promptly.
Red-flag warnings, as bullets:
Blistering or peeling in a sunburn pattern after modest exposure. Rash involving covered skin, mucous membranes, or the eyes. Fever, facial swelling, or widespread hives accompanying sun-related rash. New rash with fatigue, joint pain, or mouth ulcers, which may suggest a systemic reaction rather than simple photosensitivity. Any reaction after a dose increase or a new concurrent medication.
Do not stop methotrexate on your own. Abrupt discontinuation can flare the underlying disease, and the decision requires the prescriber.
Comparison With Other Photosensitizing Drugs
| Drug or class | Typical reaction pattern | Relative photosensitivity risk | Notes |
|---|---|---|---|
| Methotrexate | Photoexacerbation, eczematous or phototoxic eruption | Low to uncommon | Mechanism includes folate-dependent repair deficit |
| Doxycycline | Phototoxic burn-like reaction | Moderate to high | Well-documented, counseling standard |
| Hydrochlorothiazide | Phototoxic, sometimes photoallergic | Moderate | Classic offender in dermatology |
| Amiodarone | Photosensitivity with blue-gray pigmentation | Moderate to high | Cumulative dose related |
| Isotretinoin | Increased sun sensitivity | Moderate | Advised sun protection during course |
| Naproxen | Phototoxic eruption | Low to moderate | Underrecognized |
| Voriconazole | Severe phototoxicity, photocarcinogenicity | High | Requires strict photoprotection |
The comparison is qualitative. Head-to-head incidence data across these drugs do not exist in a form that supports a single ranked scale, and the table should be read as a counseling aid, not a risk calculator.
What Remains Uncertain
The honest limitation is that methotrexate photosensitivity rests on case reports, mechanistic plausibility, and drug-label cutaneous adverse effect listings rather than on controlled phototesting studies. No validated incidence figure exists. No dose threshold has been established. No biomarker predicts which patients will react.
The mechanism most likely to matter at low weekly doses, folate-dependent impairment of DNA repair, is inferred from folate biology rather than demonstrated directly in methotrexate-treated skin. That is a reasonable inference, but it is an inference. The direct photochemical route is plausible from structure but weak in practice.
What can be concluded is narrower and more useful: photosensitivity is a recognized, uncommon cutaneous effect of methotrexate, it is mechanistically coherent through at least two pathways, it is confounded by the diseases methotrexate treats, and it is managed with photoprotection rather than drug withdrawal in most cases. Patients who notice a sun-related rash should report it, photograph it, and let the prescriber weigh it against the benefits of a drug that remains a cornerstone of inflammatory disease treatment.